SL
IONS icon

Salomon & Ludwin’s Ionis Pharmaceuticals IONS Stock Holding History

Salomon & Ludwin’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Hold
332
– – ﹤0.01% 946
2026
Q1 		$24.8K Hold
332
– – ﹤0.01% 931
2025
Q4 		$26.1K Hold
332
– – ﹤0.01% 702
2025
Q3 		$23K Buy
+332
New +$16.2K ﹤0.01% 732

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Salomon & Ludwin's IONS Position: Q2 2026 in Review

Salomon & Ludwin held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 332 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Salomon & Ludwin first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Salomon & Ludwin held 332 shares of Ionis Pharmaceuticals worth $26.3K as of Q2 2026.
  • Salomon & Ludwin left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #946 holding.
  • Salomon & Ludwin first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.